Smith, Moore & Co’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Smith, Moore & Co’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-15,000	Closed	-$61K	–	167
2014 Q2	$61K	Buy	15,000 +5,000	+50%	+$21.2K	0.04%	146
2014 Q1	$53K	Buy	+10,000	New	+$56.1K	0.03%	147

Other funds holding SGYP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Smith, Moore & Co's SGYP Position: Q3 2014 in Review

Smith, Moore & Co sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q3 2014, closing a stake of 15,000 shares — an estimated $61K sold.

Smith, Moore & Co first reported a position in SGYP in Q1 2014 and held it in 2 quarters. The position peaked at $61K in Q2 2014. 78 funds tracked by Wall St. Rank hold SGYP as of Q3 2014.

Smith, Moore & Co reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q3 2014 after selling out during the quarter.
Smith, Moore & Co sold 15,000 Synergy Pharmaceuticals, Inc Common Stock shares in Q3 2014, an estimated $61K.
Smith, Moore & Co first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2014 and held it in 2 quarters.
Smith, Moore & Co's Synergy Pharmaceuticals, Inc Common Stock position peaked at $61K in Q2 2014.
78 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q3 2014.

Based on Smith, Moore & Co's 13F filing for Q3 2014, filed 7 Nov 2014.